Latest Biotech News

President Trump announced agreements with Novo Nordisk and Eli Lilly to expand access and lower prices for their obesity medicines; the administration said the deals will lower costs for some...

PacBio said Berry Genomics received National Medical Products Administration Class III approval for the Sequel II CNDx system, marking what PacBio called the first regulatory clearance for a...

Gilead Sciences reported that Trodelvy failed to meet the primary endpoint in a Phase 3 trial for a subset of breast cancer patients, representing a significant setback for the antibody‑drug...

Researchers at MIT described a new ionizable lipid nanoparticle (LNP) that improved mRNA delivery potency in mice, enabling an influenza mRNA vaccine to elicit comparable immune responses at...

Qiagen announced an agreement to acquire Seattle‑based Parse Biosciences for up to $280 million, folding a high‑throughput single‑cell library prep company into a larger public instrument and...

Novo Nordisk raised its offer for obesity biotech Metsera in a contested sale that also drew a formal staff letter from the Federal Trade Commission raising concerns about the transaction’s...

Evommune, a clinical‑stage inflammation biotech with late‑stage data in chronic inducible urticaria, priced an initial public offering for approximately $150 million and began trading on the NYSE....

Intellia Therapeutics reported the death of a patient who had been hospitalized with liver injury after receiving nex‑z, its LNP‑delivered in vivo CRISPR base‑editing therapy for transthyretin...

The Trump administration struck agreements with Novo Nordisk and Eli Lilly to lower prices and expand access to leading obesity drugs and announced plans for a government drug portal. In parallel,...

Novo Nordisk continued to raise its bid for obesity biotech Metsera amid a heated auction with Pfizer, and the Federal Trade Commission flagged concerns about the structure of Novo’s proposal. FTC...

Eli Lilly disclosed Phase 2 data linking its amylin receptor agonist eloralintide to up to 20.1% mean weight loss at 48 weeks and announced plans to start Phase 3. The data showed dose‑dependent...

Arima Genomics touted results from its Aventa Hi‑C lymphoma assay that detected clinically significant gene fusions and structural rearrangements in FFPE lymphoma samples where FISH was...

Hepta, founded by former Illumina and Grail personnel, surfaced from stealth with transformer‑based AI that reads the cell‑free DNA epigenome to detect organ‑specific chronic disease signals and...

Ginkgo Bioworks secured a BioMaP‑Consortium award from BARDA valued up to $22.2M to develop cost‑reducing, rapid domestic manufacturing technologies for monoclonal antibodies against filoviruses...

BIOVECTRA and Revolution Biomanufacturing announced a partnership to integrate Revolution’s sequence‑optimization platforms for UTRs and codon usage with BIOVECTRA’s end‑to‑end GMP capabilities...

Researchers at MIT reported a novel lipid nanoparticle that dramatically enhanced mRNA vaccine potency in preclinical work, claiming the formulation could reduce required dose by up to 100‑fold....

Mark Zuckerberg and Priscilla Chan’s Chan Zuckerberg Initiative reorganized its science portfolio and folded EvolutionaryScale into a unified Biohub effort, hiring EvolutionaryScale’s team and...

A patient in Intellia Therapeutics’ in vivo CRISPR trial for transthyretin amyloidosis (nex‑z) has died, compounding safety concerns that halted dosing in two Phase 3 studies. Intellia reported...

Two independent advances target core limitations of mRNA therapeutics: delivery potency and molecular durability. MIT researchers engineered a novel lipid nanoparticle that greatly enhances...

Eli Lilly reported robust Phase 2 results for its amylin receptor agonist eloralintide, with some cohorts reaching approximately 20% mean weight loss at 48 weeks and a tolerability profile Lilly...